Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Approaching smoldering myeloma

Shaji Kumar • 11 May 2020
COMy Virtual 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Dexamethasone Lenalidomide

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the challenges presented clinically my smoldering myeloma and how the disease is currently diagnosed and patients risk-stratified. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Shaji Kumar

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma 3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma 2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T 1:57
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
Shaji Kumar • 17 Jun 2025
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD 5:43
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
Shaji Kumar • 17 Jun 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals